All Cell Therapy Services

TESSA® technology enhances AAV vector yields up to 100x using a helper-virus-free system ideal for CAR-T and other gene-modified cell therapies. TESSA® supports higher productivity with fewer downstream purification challenges.

Minaris’ XOFLX™ Platform Packaging/Producer cell lines enable stable, scalable lentiviral vector production with less/no plasmids, supporting cost-effective LVV supply for gene-modified cell therapy programs.

From packaging and producer lines to engineered effector cells, Minaris offers cell line development services tailored to your platform, including transduction optimization, clone selection and scale-up support.

Minaris applies a robust technology transfer framework to de-risk program onboarding. Whether your process is early-stage or commercial-ready, our cross-functional teams ensure fast, efficient and traceable handoff.

Our process development scientists help you translate R&D protocols into GMP-compliant, more closed, automated workflows, optimizing yield, viability, formulation, cryopreservation, process duration and consistency across both autologous and allogeneic cell therapy platforms. Our analytical development teams have created analytical test methods that are fit for their purpose, scientifically valid, and ready for release or support clinical processes as in-process controls (IPCs). These methods meet the requirements of health authorities by describing final products’ safety, identity, strength, quality and purity.

With GMP facilities in the US, Germany and Japan, Minaris provides clinical and commercial manufacturing for cell therapies. Our sites support early-phase and late-phase production, with integrated QC testing and global regulatory alignment.